96 Chapter 4 Supplementary table 1. Baseline characteristics of vaccination group, stratified by type of vaccine. Total (n=147) mRNAVaccine (n=108) Viral Vector Vaccine (n=16) Both (n=23) Age, mean (SD) 50.3 (11.6) 49.2 (10.6) 52.1 (12.6) 54.5 (14.6) Female sex, n (%) 118 (80.3) 90 (83.3) 11 (68.8) 17 (73.9) BMI, mean (SD) 25.0 (4.4) 25.1 (4.3) 24.6 (3.3) 24.7 (5.2) Migraine without aura, n (%) 99 (67.3) 70 (64.8) 12 (75.0) 17 (73.9) Chronic migraine, n (%) 18 (12.2) 12 (11.1) 5 (31.2) 1 (4.3) Monthly migraine days, mean (SD) 6.0 (4.5) 5.9 (4.2) 7.3 (6.3) 6.1 (4.5) Monthly headache days, mean (SD) 9.0 (6.4) 8.6 (6.0) 12.5 (9.6) 8.7 (5.6) Monthly acute medication days 4.2 (2.6) 4.2 (2.6) 4.1 (3.3) 4.4 (2.6) Supplementary table 2. Change in Monthly Migraine Days (MMD) for month 1 post-vaccination compared to the baseline month, stratified by COVID-19 vaccine type. One month is defined as 28 days. Estimates 95% confidence interval p-value mRNA vaccine 1.15 0.63 – 1.67 <0.001 Viral vector vaccine 0.65 -0.34 – 1.64 0.198
RkJQdWJsaXNoZXIy MjY0ODMw